Abstract
Rheumatic diseases distinctly affect women of childbearing age, creating complex challenges in balancing maternal disease control with fetal safety during pregnancy and lactation. This review summarizes the pathophysiology and management of common rheumatic diseases, with a focus on the safety and efficacy of conventional and biologic disease-modifying antirheumatic drugs (DMARDs). Particular emphasis is placed on pregnancy-compatible therapies, contraindicated agents, and emerging evidence supporting the use of select biologics such as tumor necrosis factor inhibitors (TNKs). Current guidelines and primary literature have been reviewed to show the importance of preconception counseling and individualized treatment plans to optimize maternal and fetal outcomes.
Recommended Citation
Rawa A, Ghattas K. Rheumatic Diseases in Pregnancy: Emerging Pharmacologic Management and Safety. Transformative Medicine. 2025; 4(4):75-77. doi: https://doi.org/10.54299/tmed/anri3177.